Guanidinoacetate methyltransferase deficiency: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Guanidinoacetate methyltransferase deficiency | |||
| image = [[File:Creatine_neutral.png|alt=Creatine molecule]] | |||
| caption = [[Creatine]] | |||
| synonyms = GAMT deficiency | |||
| pronounce = | |||
| specialty = [[Medical genetics]] | |||
| symptoms = [[Developmental delay]], [[seizures]], [[extrapyramidal symptoms]], [[intellectual disability]] | |||
| onset = [[Infancy]] | |||
| duration = Lifelong | |||
| causes = Mutations in the [[GAMT gene]] | |||
| risks = | |||
| diagnosis = [[Genetic testing]], [[magnetic resonance spectroscopy]] | |||
| differential = [[Cerebral creatine deficiency syndromes]] | |||
| prevention = | |||
| treatment = [[Creatine supplementation]], [[dietary modification]] | |||
| medication = | |||
| prognosis = Variable | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
{{Short description|A rare metabolic disorder affecting creatine synthesis}} | {{Short description|A rare metabolic disorder affecting creatine synthesis}} | ||
'''Guanidinoacetate methyltransferase deficiency''' (GAMT deficiency) is a rare [[autosomal recessive]] [[metabolic disorder]] that affects the body's ability to synthesize [[creatine]], an essential compound for energy storage and utilization in [[muscle]] and [[brain]] tissues. This condition is characterized by a deficiency in the enzyme guanidinoacetate methyltransferase, which is crucial for the conversion of [[guanidinoacetate]] to [[creatine]]. | '''Guanidinoacetate methyltransferase deficiency''' (GAMT deficiency) is a rare [[autosomal recessive]] [[metabolic disorder]] that affects the body's ability to synthesize [[creatine]], an essential compound for energy storage and utilization in [[muscle]] and [[brain]] tissues. This condition is characterized by a deficiency in the enzyme guanidinoacetate methyltransferase, which is crucial for the conversion of [[guanidinoacetate]] to [[creatine]]. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Guanidinoacetate methyltransferase deficiency results from mutations in the [[GAMT gene]], which encodes the enzyme responsible for the methylation of guanidinoacetate to form creatine. This enzymatic step is the final stage in the [[creatine synthesis]] pathway. The deficiency leads to an accumulation of guanidinoacetate and a depletion of creatine in the body. Elevated levels of guanidinoacetate are neurotoxic and contribute to the neurological symptoms observed in affected individuals. | Guanidinoacetate methyltransferase deficiency results from mutations in the [[GAMT gene]], which encodes the enzyme responsible for the methylation of guanidinoacetate to form creatine. This enzymatic step is the final stage in the [[creatine synthesis]] pathway. The deficiency leads to an accumulation of guanidinoacetate and a depletion of creatine in the body. Elevated levels of guanidinoacetate are neurotoxic and contribute to the neurological symptoms observed in affected individuals. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
The clinical manifestations of GAMT deficiency typically appear in infancy or early childhood. Common symptoms include: | The clinical manifestations of GAMT deficiency typically appear in infancy or early childhood. Common symptoms include: | ||
| Line 13: | Line 33: | ||
* [[Movement disorders]] | * [[Movement disorders]] | ||
* Behavioral problems such as [[autism spectrum disorder]]-like features | * Behavioral problems such as [[autism spectrum disorder]]-like features | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of guanidinoacetate methyltransferase deficiency is based on clinical evaluation, biochemical testing, and genetic analysis. Key diagnostic tests include: | Diagnosis of guanidinoacetate methyltransferase deficiency is based on clinical evaluation, biochemical testing, and genetic analysis. Key diagnostic tests include: | ||
| Line 19: | Line 38: | ||
* [[Magnetic resonance spectroscopy]] (MRS) to assess brain creatine levels | * [[Magnetic resonance spectroscopy]] (MRS) to assess brain creatine levels | ||
* Genetic testing to identify mutations in the GAMT gene | * Genetic testing to identify mutations in the GAMT gene | ||
==Treatment== | ==Treatment== | ||
The primary treatment for GAMT deficiency involves dietary supplementation to restore creatine levels and reduce guanidinoacetate accumulation. Treatment strategies include: | The primary treatment for GAMT deficiency involves dietary supplementation to restore creatine levels and reduce guanidinoacetate accumulation. Treatment strategies include: | ||
| Line 25: | Line 43: | ||
* [[Ornithine]] supplementation to reduce guanidinoacetate production | * [[Ornithine]] supplementation to reduce guanidinoacetate production | ||
* Dietary restriction of [[arginine]] and [[protein]] to lower guanidinoacetate levels | * Dietary restriction of [[arginine]] and [[protein]] to lower guanidinoacetate levels | ||
Early diagnosis and treatment are crucial to improving outcomes and preventing irreversible neurological damage. | Early diagnosis and treatment are crucial to improving outcomes and preventing irreversible neurological damage. | ||
==Prognosis== | ==Prognosis== | ||
With early and appropriate treatment, individuals with GAMT deficiency can experience significant improvements in symptoms and quality of life. However, untreated or late-diagnosed cases may result in severe intellectual disability and persistent neurological issues. | With early and appropriate treatment, individuals with GAMT deficiency can experience significant improvements in symptoms and quality of life. However, untreated or late-diagnosed cases may result in severe intellectual disability and persistent neurological issues. | ||
==See also== | |||
== | |||
* [[Creatine deficiency syndromes]] | * [[Creatine deficiency syndromes]] | ||
* [[Metabolic disorders]] | * [[Metabolic disorders]] | ||
* [[Inborn errors of metabolism]] | * [[Inborn errors of metabolism]] | ||
[[Category:Metabolic disorders]] | [[Category:Metabolic disorders]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
Latest revision as of 02:12, 7 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Guanidinoacetate methyltransferase deficiency | |
|---|---|
| |
| Synonyms | GAMT deficiency |
| Pronounce | |
| Specialty | Medical genetics |
| Symptoms | Developmental delay, seizures, extrapyramidal symptoms, intellectual disability |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the GAMT gene |
| Risks | |
| Diagnosis | Genetic testing, magnetic resonance spectroscopy |
| Differential diagnosis | Cerebral creatine deficiency syndromes |
| Prevention | |
| Treatment | Creatine supplementation, dietary modification |
| Medication | |
| Prognosis | Variable |
| Frequency | Rare |
| Deaths | |
A rare metabolic disorder affecting creatine synthesis
Guanidinoacetate methyltransferase deficiency (GAMT deficiency) is a rare autosomal recessive metabolic disorder that affects the body's ability to synthesize creatine, an essential compound for energy storage and utilization in muscle and brain tissues. This condition is characterized by a deficiency in the enzyme guanidinoacetate methyltransferase, which is crucial for the conversion of guanidinoacetate to creatine.
Pathophysiology[edit]
Guanidinoacetate methyltransferase deficiency results from mutations in the GAMT gene, which encodes the enzyme responsible for the methylation of guanidinoacetate to form creatine. This enzymatic step is the final stage in the creatine synthesis pathway. The deficiency leads to an accumulation of guanidinoacetate and a depletion of creatine in the body. Elevated levels of guanidinoacetate are neurotoxic and contribute to the neurological symptoms observed in affected individuals.
Clinical Presentation[edit]
The clinical manifestations of GAMT deficiency typically appear in infancy or early childhood. Common symptoms include:
- Developmental delay
- Intellectual disability
- Seizures
- Hypotonia
- Movement disorders
- Behavioral problems such as autism spectrum disorder-like features
Diagnosis[edit]
Diagnosis of guanidinoacetate methyltransferase deficiency is based on clinical evaluation, biochemical testing, and genetic analysis. Key diagnostic tests include:
- Measurement of guanidinoacetate and creatine levels in urine and blood
- Magnetic resonance spectroscopy (MRS) to assess brain creatine levels
- Genetic testing to identify mutations in the GAMT gene
Treatment[edit]
The primary treatment for GAMT deficiency involves dietary supplementation to restore creatine levels and reduce guanidinoacetate accumulation. Treatment strategies include:
- Creatine monohydrate supplementation
- Ornithine supplementation to reduce guanidinoacetate production
- Dietary restriction of arginine and protein to lower guanidinoacetate levels
Early diagnosis and treatment are crucial to improving outcomes and preventing irreversible neurological damage.
Prognosis[edit]
With early and appropriate treatment, individuals with GAMT deficiency can experience significant improvements in symptoms and quality of life. However, untreated or late-diagnosed cases may result in severe intellectual disability and persistent neurological issues.
